Research Report on Claudin 18.2 in Gastric Cancer and Gastroesophageal Junction Adenocarcinoma Background Introduction Gastric cancer and gastroesophageal junction (G/GEJ) adenocarcinoma are major global health burdens. It is estimated that in 2020 alone, there were approximately 1.7 million new cases of gastric and esophageal cancers worldwide, wi...

The Use of Regorafenib in Patients with BRAF-Mutant Solid Tumors: A Summary of Results from the TAPUR Study Background Introduction The BRAF gene belongs to the cytoplasmic serine/threonine kinase family and regulates cell proliferation and survival by activating the mitogen-activated protein kinase signaling pathway (MAPK). BRAF mutations can lead...

In contemporary clinical oncology practice and drug development, the methods for evaluating tumor response are on the cusp of a revolution. Since the World Health Organization (WHO) proposed tumor response classification criteria for assessing the effectiveness of anti-cancer drugs in 1981, this field has undergone several improvements. Notably, th...

Phase II Study of Erdafitinib in Patients with FGFR Amplifications: A Detailed Report Background Dysregulation of Fibroblast Growth Factor Receptor (FGFR) family signaling pathways is widely recognized to be associated with cancer development, progression, and treatment resistance. This study primarily investigates tumors with FGFR1-4 amplification...

Overall Survival and Treatment Patterns in Metastatic Castration-Resistant Prostate Cancer Patients Based on PTEN Status Academic Background Prostate cancer is one of the most common malignant tumors among men worldwide and a leading cause of cancer-related deaths. Approximately 10%-20% of prostate cancer patients will develop castration-resistant ...